Glycogen synthase kinase-3 beta (GSK3B) (GSK3B)

Glycogen synthase kinase-3 beta (GSK3β) is a multifunctional serine/threonine kinase that serves as a critical regulator of the NLRP3 inflammasome activation pathway (UniProt P49841). In this signaling cascade, GSK3β facilitates the "priming" of the inflammasome by promoting NF-κB-mediated transcription of NLRP3 and pro-inflammatory cytokines (Wang et al., 2018, J. Biol. Chem.). It also plays a role in the "activation" step by modulating mitochondrial reactive oxygen species (ROS) production and ionic fluxes that trigger the assembly of the NLRP3 complex (Guan et al., 2019, Aging). Dysregulation of the GSK3β-NLRP3 axis is heavily implicated in the pathogenesis of chronic inflammatory conditions and neurodegenerative disorders, such as Alzheimer's disease and type 2 diabetes (Kerr et al., 2018, J. Neuroinflammation). Pharmacological inhibition of GSK3β using agents like lithium or small-molecule inhibitors (e.g., CHIR-99021) has been shown to suppress NLRP3-mediated inflammation in various disease models (PubMed PMC5949131). However, because GSK3β is a central component of the Wnt/β-catenin signaling pathway, its systemic inhibition carries risks of off-target effects, including potential oncogenicity and metabolic disturbances (StatPearls, Glycogen Synthase Kinase 3). Consequently, therapeutic strategies targeting this pathway must carefully balance anti-inflammatory efficacy with the maintenance of homeostatic signaling.

Other names

GSK3-betaGSK3BGlycogen synthase kinase 3 betaGSK3β-NLRP3 axisGSK3β-mediated NLRP3 inflammasome activation pathway

Inhibition of Glycogen synthase kinase-3 beta (GSK3B) activity suppresses the priming and assembly of the NLRP3 inflammasome complex, thereby reducing the maturation and secretion of pro-inflammatory cytokines like IL-1β and IL-18.